Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06127667
Other study ID # PT-2023-32375
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date April 1, 2028

Study information

Verified date April 2024
Source University of Minnesota
Contact Jacqueline Palmer
Phone 240-446-1168
Email palmerj@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are neurotypical and cognitively normal. The primary outcome from a clinical trials perspective will be cerebrovascular response to a bout of aerobic exercise (i.e. change in cerebral blood flow with the performance of aerobic exercise on a recumbent stepper exercise machine). Non-interventional outcomes will be EEG measures of cortical activity and biomechanical kinetic and kinematic data recorded during standing balance reactions, as well as biological blood samples for genomic analysis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 102
Est. completion date April 1, 2028
Est. primary completion date April 1, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 95 Years
Eligibility Inclusion Criteria: - Age within the following 3 group age ranges, 21-30yo; middle-aged: 40-55yo; older: 65-95yo adults - the absence of major orthopedic disability - cognitively normal (MoCA score = 26/30 in older adult group) - vision that is 20/40 or better with or without corrective lenses, (5) the ability to consent and communicate with researchers - English speaking - ability to stand for 3 minutes and walk 10 meters with or without an assistive device and without the assistance of another person. Exclusion Criteria: - insulin-dependent diabetes - peripheral neuropathy - myocardial infarction or symptoms of coronary artery disease within 2 years - congestive heart failure or class IV heart failure - any significant sensory impairment affecting balance or cognition; visual, vestibular, or auditory impairments.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
aerobic exercise
use of single bout of aerobic exercise

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary cerebral blood flow velocity assessed using transcranial Doppler ultrasound Includes recordings from transcranial Doppler ultrasound of cerebral blood flow (CBF) velocity performed at the first session during rest, sit-to-stand, transfer, and single bout of aerobic exercise. 1 week
Primary Kinetic center of pressure rate of rise post-balance perturbation, assessed biomechanically. Recordings from 64-channels of EEG electrodes, kinetic, and kinematic biomechanical data during standing balance reactions will be collected. 1 week
Primary Prefrontal-M1 coherence an S1-M1 coherence post-balance perturbation, assessed using EEG Recordings from 64-channels of EEG electrodes, kinetic, and kinematic biomechanical data during standing balance reactions will be collected. 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT05456503 - PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620 Phase 3
Completed NCT03903211 - Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease Phase 2